Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial.

被引：0
|
作者：
Fukasawa, Satoshi
Suzuki, Hiroyoshi
Sato, Fuminori
Hashine, Katsuyoshi
Hasumi, Hisashi
Matsumoto, Hiroaki
Tsuchiya, Tomohiro
Uemura, Hirotsugu
Oya, Mototsugu
Kanayama, Hiroomi
Kawaguchi, Kazushiro
Noguchi, Hidehisa
Enjo, Kentaro
Tran, Namphuong
Todd, Mary Beth
Fizazi, Karim
Matsubara, Nobuaki
机构：
[1] Chiba Canc Ctr Hosp, Chiba, Japan
[2] Toho Univ, Sakura Med Ctr, Sakura, Japan
[3] Oita Univ, Oita, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[5] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan
[6] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan
[7] Gifu Univ, Grad Sch Med, Gifu, Japan
[8] Kinki Univ, Sch Med, Osaka, Japan
[9] Keio Univ, Sch Med, Tokyo, Japan
[10] Tokushima Univ, Grad Sch, Tokushima, Japan
[11] Janssen Pharmaceut K K, Tokyo, Japan
[12] Janssen Pharmaceut K K, Chiyoda Ku, Tokyo, Japan
[13] Janssen Res Dev, LLC, Los Angeles, CA USA
[14] Janssen Global Serv, Raritan, NJ USA
[15] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[16] Natl Canc Ctr Hosp E, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.286
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher J.
    Shore, Neal D.
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Van Poppel, Hendrik
    Carles, Joan
    Flaig, Thomas W.
    Efstathiou, Eleni
    Yu, Evan Y.
    Higano, Celestia S.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Todd, Mary B.
    Yu, Margaret K.
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    Saad, Fred
    EUROPEAN UROLOGY, 2014, 66 (05) : 815 - 825
  • [42] Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
    Clarke, Caroline S.
    Hunter, Rachael M.
    Gabrio, Andrea
    Brawley, Christopher D.
    Ingleby, Fiona C.
    Dearnaley, David P.
    Matheson, David
    Attard, Gerhardt
    Rush, Hannah L.
    Jones, Rob J.
    Cross, William
    Parker, Chris
    Russell, J. Martin
    Millman, Robin
    Gillessen, Silke
    Malik, Zafar
    Lester, Jason F.
    Wylie, James
    Clarke, Noel W.
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    James, Nicholas D.
    PLOS ONE, 2022, 17 (06):
  • [43] Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
    Logothetis, Christopher J.
    Basch, Ethan
    Molina, Arturo
    Fizazi, Karim
    North, Scott A.
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B.
    Mainwaring, Paul N.
    Sternberg, Cora N.
    Efstathiou, Eleni
    Gagnon, Dennis D.
    Rothman, Margaret
    Hao, Yanni
    Liu, Cameron S.
    Kheoh, Thian S.
    Haqq, Christopher M.
    Scher, Howard I.
    de Bono, Johann S.
    LANCET ONCOLOGY, 2012, 13 (12): : 1210 - 1217
  • [44] Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-related Events in Patients with Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial
    Xylinas, Evanguelos
    Kluth, Luis
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2013, 63 (06) : 1132 - 1133
  • [45] Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2013, 189 (05): : 1715 - 1715
  • [46] Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER plus metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy.
    O'Shaughnessy, Joyce
    Yu, Margaret K.
    Kearney, Jill
    Larsen, Julie S.
    Molina, Arturo
    Johnston, Stephen R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel
    Scher, H. I.
    Heller, G.
    Molina, A.
    Kheoh, T. S.
    Attard, G.
    Moreira, J.
    Sandhu, S. K.
    Parker, C.
    Logothetis, C.
    McCormack, R. T.
    Fizazi, K.
    Anand, A.
    Danila, D. C.
    Fleisher, M.
    Olmos, D.
    Haqq, C. M.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [48] Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.
    Scher, H. I.
    Heller, G.
    Molina, A.
    Kheoh, T. S.
    Attard, G.
    Moreira, J.
    Sandhu, S. K.
    Parker, C.
    Logothetis, C.
    McCormack, R. T.
    Fizazi, K.
    Anand, A.
    Danila, D. C.
    Fleisher, M.
    Olmos, D.
    Haqq, C. M.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY
    Fizazi, K.
    De Bono, J.
    Haqq, C.
    Logothetis, C. C.
    Jones, R. J.
    Chi, K.
    Kheoh, T.
    Molina, A.
    Scher, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 338 - 338
  • [50] Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66 Metastatic Hormone-naive Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease
    Di Nunno, Vincenzo
    Santoni, Matteo
    Gatto, Lidia
    Mollica, Veronica
    Massari, Francesco
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 390 - 390
12345